HK1171226A1 - Azaindole glucokinase activators - Google Patents

Azaindole glucokinase activators

Info

Publication number
HK1171226A1
HK1171226A1 HK12112005.4A HK12112005A HK1171226A1 HK 1171226 A1 HK1171226 A1 HK 1171226A1 HK 12112005 A HK12112005 A HK 12112005A HK 1171226 A1 HK1171226 A1 HK 1171226A1
Authority
HK
Hong Kong
Prior art keywords
azaindole
glucokinase activators
glucokinase
activators
azaindole glucokinase
Prior art date
Application number
HK12112005.4A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文．約瑟夫．貝特爾
陳力
溫迪．萊亞．科比特
馮立春
南希-埃倫．海恩斯
羅伯特．弗朗西斯．凱斯特
蘇松塞
杰斐遜．賴特．蒂利
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1171226A1 publication Critical patent/HK1171226A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK12112005.4A 2009-12-14 2012-11-23 Azaindole glucokinase activators HK1171226A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28611609P 2009-12-14 2009-12-14
PCT/EP2010/069455 WO2011073117A1 (fr) 2009-12-14 2010-12-13 Activateurs de glucokinase azaindole

Publications (1)

Publication Number Publication Date
HK1171226A1 true HK1171226A1 (en) 2013-03-22

Family

ID=43629190

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12112005.4A HK1171226A1 (en) 2009-12-14 2012-11-23 Azaindole glucokinase activators

Country Status (11)

Country Link
US (1) US8222416B2 (fr)
EP (1) EP2513103A1 (fr)
JP (1) JP5763093B2 (fr)
KR (1) KR20120104357A (fr)
CN (1) CN102686587B (fr)
BR (1) BR112012014463A8 (fr)
CA (1) CA2782172A1 (fr)
HK (1) HK1171226A1 (fr)
MX (1) MX2012006287A (fr)
RU (1) RU2593369C2 (fr)
WO (1) WO2011073117A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106518866A (zh) * 2016-09-20 2017-03-22 北京万全德众医药生物技术有限公司 一种可用作葡糖激酶活化剂的氮杂吲哚类化合物
WO2018055316A1 (fr) 2016-09-26 2018-03-29 Centre National De La Recherche Scientifique Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives
WO2018097273A1 (fr) 2016-11-28 2018-05-31 Eisai R&D Management Co., Ltd. Sels de dérivé d'indazole et leurs cristaux
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506980A (ja) * 1996-11-19 2001-05-29 アムジエン・インコーポレーテツド アリールおよびヘテロアリール置換縮合ピロール抗炎症剤
AU3210799A (en) * 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
ATE278680T1 (de) 1999-03-29 2004-10-15 Hoffmann La Roche Glukokinase aktivatoren
JP3788935B2 (ja) 2000-05-03 2006-06-21 エフ．ホフマン−ラ ロシュ アーゲー アルキニルフェニルヘテロ芳香族グルコキナーゼ活性化物質
DK1283830T3 (da) 2000-05-08 2008-08-25 Hoffmann La Roche Para-amin-substituerede phenylamidglucokinase-aktivatorer
DE60106599T2 (de) 2000-05-08 2006-02-09 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
AU2002221902B2 (en) * 2000-12-06 2006-11-23 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
PT1501815E (pt) 2002-04-26 2007-01-31 Hoffmann La Roche Fenilacetamidas substituídas e a sua utilização como activadores de glicocinase
KR20050074959A (ko) 2002-10-03 2005-07-19 노파르티스 아게 제ｉｉ형 당뇨병 치료에 유용한 글루코키나아제 활성인자로서의 치환된 (티아졸-２-일)-아미드 또는 술폰아미드
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1594863A1 (fr) 2003-02-11 2005-11-16 Prosidion Limited Composes d'amide a substitution tri(cyclo), activateurs de la glucokinase
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
US7432287B2 (en) 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
JP2007523905A (ja) 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
KR20070007103A (ko) 2004-02-18 2007-01-12 아스트라제네카 아베 벤즈아미드 유도체 및 이의 글루코키나아제 활성화제로서의용도
US7687502B2 (en) 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
BRPI0509573A (pt) 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
EA012204B1 (ru) 2004-04-21 2009-08-28 Прозидион Лимитед Три(цикло)замещённые амидные соединения
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
EP1824835A1 (fr) 2004-12-03 2007-08-29 Novo Nordisk A/S Composes heteroaromatiques activants de glukokinase
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US20080234273A1 (en) 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
JP4651714B2 (ja) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体
JP2009500442A (ja) 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
NZ564743A (en) 2005-07-11 2010-03-26 Mitsubishi Tanabe Pharma Corp An oxime derivative as a glucokinase activating agent and preparations thereof
JP2009504621A (ja) 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
US20090281142A1 (en) 2005-08-31 2009-11-12 Astellas Pharma Inc. Thiazole derivative
EP1928874A1 (fr) 2005-09-16 2008-06-11 AstraZeneca AB Composés hétérobicycliques utilisés comme activateurs de la glucokinase
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
JP2009514836A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
EP1948644A1 (fr) 2005-11-03 2008-07-30 Prosidion Limited Amides a substitution tricyclo
ATE442368T1 (de) 2005-11-30 2009-09-15 Hoffmann La Roche 3-amino-2-arylpropylazaindole und anwendungen davon
DE602006014305D1 (de) * 2005-12-16 2010-06-24 Hoffmann La Roche Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
WO2008136428A1 (fr) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited Composé hétérocyclique à cinq chaînons à teneur en azote

Also Published As

Publication number Publication date
MX2012006287A (es) 2012-07-03
US20110144105A1 (en) 2011-06-16
JP5763093B2 (ja) 2015-08-12
JP2013513639A (ja) 2013-04-22
EP2513103A1 (fr) 2012-10-24
BR112012014463A2 (pt) 2017-03-14
CN102686587A (zh) 2012-09-19
CN102686587B (zh) 2015-05-27
CA2782172A1 (fr) 2011-06-23
BR112012014463A8 (pt) 2017-12-26
WO2011073117A1 (fr) 2011-06-23
US8222416B2 (en) 2012-07-17
RU2012127273A (ru) 2014-01-27
RU2593369C2 (ru) 2016-08-10
KR20120104357A (ko) 2012-09-20

Similar Documents

Publication Publication Date Title
ZA201007975B (en) Glucokinase activators
HK1164281A1 (en) Benzofuranyl derivatives used as glucokinase activators
ZA201006822B (en) Glucokinase activators
HK1173142A1 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives n1--5-
HK1177462A1 (en) Triazolopyridine derivatives
HK1172893A1 (en) 5-fluoropyrimidinone derivatives 5-
ZA201109385B (en) Bace inhibitors
IL219087A0 (en) Benzimidazole-imidazole derivatives
EP2415443A4 (fr) Lit
EP2391627A4 (fr) Hétérocycles pyrazolo bicycliques
IL216007A0 (en) Isoxazole-pyridine derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
IL213927A0 (en) Deoxyactagardine derivatives
HK1172894A1 (en) N1-acyl-5-fluoropyrimidinone derivatives n1--5-
HK1169623A1 (en) Pyrazinooxazepine derivatives
IL219603A0 (en) Imidazopyridine derivatives
PT2223593T (pt) Nebulizador
GB0918922D0 (en) Aminopyridine derivatives
HK1171226A1 (en) Azaindole glucokinase activators
GB201017730D0 (en) Bed
HUE039414T2 (hu) Ágy
GB2521926B (en) Supply unit
HK1154228A1 (en) Carriage
GB0918924D0 (en) Azaindole derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181207